G Bertini1, S Perugi, C Dani, D Prisco, C Fonda. 1. Neonatal Intensive Care Unit, Department of Critical Care Medicine and Surgery, Azienda Ospedaliera Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy. giovanna.bertini@unifi.it
Abstract
BACKGROUND: The case of a term IUGR newborn who presented a cerebral vein thrombosis diagnosed by routine ultrasound brain scan, and confirmed by magnetic resonance imaging and magnetic resonance venography, is reported. A thrombosis of cortical cerebral veins and intracerebral haemorrhage in the right frontal paramedian region was observed. METHODS: Treatment with enoxaparin was started at the initial dose of 0.5 mg/kg subcutaneously every 12 h and then at 1.25 mg/kg per 12 h in order to obtain anti-factor Xa levels between 0.5 and 1.0 U/ml. After hospital discharge, enoxaparin was continued for 2 months with a lower dose (1.8 mg/kg/die). CONCLUSION: Treatment with enoxaparin was effective as demonstrated by a complete "restitutio ad integrum".
BACKGROUND: The case of a term IUGR newborn who presented a cerebral vein thrombosis diagnosed by routine ultrasound brain scan, and confirmed by magnetic resonance imaging and magnetic resonance venography, is reported. A thrombosis of cortical cerebral veins and intracerebral haemorrhage in the right frontal paramedian region was observed. METHODS: Treatment with enoxaparin was started at the initial dose of 0.5 mg/kg subcutaneously every 12 h and then at 1.25 mg/kg per 12 h in order to obtain anti-factor Xa levels between 0.5 and 1.0 U/ml. After hospital discharge, enoxaparin was continued for 2 months with a lower dose (1.8 mg/kg/die). CONCLUSION: Treatment with enoxaparin was effective as demonstrated by a complete "restitutio ad integrum".
Authors: S Hofmann; R Knoefler; N Lorenz; G Siegert; J Wendisch; D Mueller; H Taut-Sack; J Dinger; M Kabus Journal: Thromb Res Date: 2001-09-01 Impact factor: 3.944